20.47

0.84% 0.17

Enliven Therapeutics Inc (ELVN)

Overview News Price History Option Chain Financials Discussions Forecast

Enliven Therapeutics Inc stock is traded at $20.47, with a volume of 402.43K. It is up +0.84% in the last 24 hours and up +0.99% over the past month. Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

Previous Close:

$20.30

Open:

$20.11

24h Volume:

402.43K

Relative Volume:

0.81

Market Cap:

$1.21B

Revenue:

Net Income/Loss:

$-85.21M

P/E Ratio:

-10.83

EPS:

-1.89

Net Cash Flow:

$-68.53M

1W Performance:

+6.67%

1M Performance:

+0.99%

6M Performance:

+4.01%

1Y Performance:

-19.85%

1-Day Range:

$19.97

$20.90

1-Week Range:

$18.28

$20.90

52-Week Range:

$13.30

$30.03

Enliven Therapeutics Inc Stock (ELVN) Company Profile

Name

Enliven Therapeutics Inc

Sector

Healthcare (1147)

Industry

Biotechnology (641)

Phone

720-647-8519

Address

6200 LOOKOUT ROAD, BOULDER

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

ELVN's Discussions on Twitter

Compare ELVN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ELVN Enliven Therapeutics Inc	20.47	1.20B	0	-85.21M	-68.53M	-1.89
VRTX Vertex Pharmaceuticals Inc	391.64	101.35B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	456.00	58.66B	2.46B	-319.09M	-52.09M	-2.47
REGN Regeneron Pharmaceuticals Inc	562.27	59.43B	14.21B	4.46B	3.56B	39.68
ARGX Argen X Se Adr	737.56	44.01B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	340.70	36.56B	3.81B	-644.79M	-669.77M	-6.24

Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-16-25	Initiated	Goldman	Buy
Dec-13-24	Initiated	BTIG Research	Buy
Sep-09-24	Initiated	H.C. Wainwright	Buy
Jun-11-24	Initiated	Robert W. Baird	Outperform
Apr-09-24	Initiated	Mizuho	Buy
Mar-29-23	Initiated	Jefferies	Buy

View All

Enliven Therapeutics Inc Stock (ELVN) Latest News

Sep 30, 2025

Chart based exit strategy for Enliven Therapeutics Inc.Quarterly Profit Summary & Consistent Growth Equity Picks - newser.com

Sep 30, 2025

Long term hold vs stop loss in Enliven Therapeutics Inc.Quarterly Risk Review & Weekly Market Pulse Alerts - newser.com

Sep 30, 2025

Is now a turning point for Enliven Therapeutics Inc.Insider Buying & Stepwise Trade Signal Guides - newser.com

Sep 30, 2025

Sep 29, 2025

Top chart patterns to watch in Enliven Therapeutics Inc.2025 Big Picture & Weekly High Return Opportunities - newser.com

Sep 29, 2025

Will Enliven Therapeutics Inc. stock recover after recent dropWeekly Trend Recap & Long-Term Safe Investment Plans - newser.com

Sep 29, 2025

Will Enliven Therapeutics Inc. rebound enough to break even2025 Top Decliners & Weekly High Potential Stock Alerts - newser.com

Sep 29, 2025

Why retail investors favor Enliven Therapeutics Inc. stockInsider Selling & Free Daily Entry Point Trade Alerts - newser.com

Sep 29, 2025

Developing predictive dashboards with Enliven Therapeutics Inc. dataJuly 2025 Patterns & Fast Exit and Entry Strategy Plans - newser.com

Sep 29, 2025

Sep 28, 2025

What analysts say about Enliven Therapeutics Inc stockGlobal Market Influence & Investment Case Studies - earlytimes.in

Sep 28, 2025

How to manage a losing position in Enliven Therapeutics Inc.2025 Valuation Update & Precise Buy Zone Identification - newser.com

Sep 28, 2025

Head-To-Head Analysis: Enliven Therapeutics (NASDAQ:ELVN) vs. Crinetics Pharmaceuticals (NASDAQ:CRNX) - Defense World

Sep 28, 2025

Sep 27, 2025

Brokerages Set Enliven Therapeutics, Inc. (NASDAQ:ELVN) Price Target at $41.20 - Defense World

Sep 27, 2025

Enliven Therapeutics Inc Stock Analysis and ForecastFundamental Strength Indicators & Low Risk Wealth Building - Early Times

Sep 27, 2025

Sep 26, 2025

Enliven Therapeutics (NASDAQ:ELVN) Trading 7.2% HigherTime to Buy? - MarketBeat

Sep 26, 2025

Sep 25, 2025

Insider Selling: Enliven Therapeutics (NASDAQ:ELVN) CEO Sells 2,800 Shares of Stock - MarketBeat

Sep 25, 2025

Enliven Therapeutics (NASDAQ:ELVN) Insider Joseph Lyssikatos Sells 1,500 Shares - MarketBeat

Sep 25, 2025

Enliven Therapeutics CSO sells $30,045 in shares By Investing.com - Investing.com Canada

Sep 25, 2025

Sep 24, 2025

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Average Recommendation of "Buy" by Brokerages - MarketBeat

Sep 24, 2025

Sep 23, 2025

Enliven Therapeutics CSO sells shares worth $135,697 - Investing.com India

Sep 23, 2025

Enliven Therapeutics CSO sells shares worth $135,697 By Investing.com - Investing.com Canada

Sep 23, 2025

Enliven Therapeutics (NASDAQ:ELVN) Insider Joseph Lyssikatos Sells 7,000 Shares - MarketBeat

Sep 23, 2025

Samuel Kintz Sells 5,000 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock - MarketBeat

Sep 23, 2025

Insider Selling: Enliven Therapeutics (NASDAQ:ELVN) CEO Sells 1,000 Shares of Stock - MarketBeat

Sep 23, 2025

Sep 22, 2025